Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ: PACB) is joining the iHope global rare-disease genomics network as its first long-read sequencing partner to integrate HiFi long-read whole-genome sequencing.
iHope supports more than 1,000 patients annually across 25 clinical sites in 14 countries. Integration is expected to begin in early 2026 and aims to improve detection of challenging variants and support future precision-therapeutic research.
PacBio (NASDAQ: PACB) completed the sale of select short-read sequencing intellectual property and related assets to Illumina, closing January 30, 2026. PacBio received $48.1 million in net cash proceeds, Illumina assumed certain liabilities, and granted PacBio a non-exclusive license back to specified intellectual property.
PacBio said the transaction sharpens its focus on long-read sequencing, accelerates SPRQ-Nx chemistry development, and strengthens the company balance sheet.
PacBio (NASDAQ: PACB) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. A quarterly conference call and webcast will be held at 5:00 PM Eastern Time (2:00 PM Pacific) and will be accessible via PacBio's investor website.
Investors can listen live via the webcast or by phone: toll-free 1-888-349-0136 or international 1-412-317-0459. A replay will be available on the investor site after the call.
PacBio (NASDAQ: PACB) announced on Jan 12, 2026 plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare to apply HiFi long‑read whole‑genome sequencing to support individualized antisense oligonucleotide (ASO) therapies for ultra‑rare genetic diseases. PacBio will donate sequencing reagents and provide scientific resources to enable variant phasing, structural variant detection, repeat expansion resolution, and regulatory‑grade molecular characterization to inform ASO target identification, design feasibility, and regulatory documentation. The collaboration aims to reduce sequential tests, accelerate target validation, and strengthen end‑to‑end genomics‑driven therapy development for n‑of‑1 patients.
PacBio (NASDAQ: PACB) announced on Jan 12, 2026 that a UW Medicine and Seattle Children’s research team will use HiFi whole-genome sequencing on PacBio Revio with SPRQ-Nx chemistry as a first-line approach to investigate Sudden Unexplained Death in Childhood (SUDC). The study will sequence trios from 200 families (child plus parents), prioritize long-read HiFi data for comprehensive variant detection, and join the HiFi Solves Global Consortium. The approach aims to simplify workflows for challenging inputs (post-mortem tissue, newborn dried blood spots) and to increase diagnostic yield by resolving structural variants, tandem repeats, and by identifying de novo versus inherited contributors to risk. PacBio provides in-kind support and the project is backed by the SUDC Foundation.
PacBio (NASDAQ: PACB) reported preliminary unaudited revenue of $44.6M for Q4 2025 (+14% YoY) and $160.0M for full year 2025 (+4% YoY).
Q4 drivers included higher Revio and Vega shipments and a record $21.6M in consumables revenue. Instrument revenue declined to $17.3M in Q4 and $53.8M for 2025 versus prior-year instrument revenue of $65.8M. Service and other revenue rose to $5.7M in Q4 and $24.3M for 2025.
System placements: Revio 21 in Q4 (61 for 2025) and Vega 42 in Q4 (140 for 2025). Ending cash, cash equivalents, and investments were about $279.5M. Results are preliminary and expected to be finalized in the 2025 Form 10-K and a February earnings call.
PacBio (NASDAQ: PACB) and UC Davis researchers introduced CiFi, a community-developed method that combines multi-contact chromatin conformation capture (3C) with PacBio HiFi long-read sequencing to produce chromosome-scale, haplotype-resolved assemblies from a single Revio sequencing run.
CiFi generates long, concatemeric HiFi reads that capture multiple chromatin interactions per molecule, improving mapping in repetitive regions, enabling multi-contact resolution, and reducing input material, libraries, and sequencing runs. A Nature Communications publication and demonstration on prairie and meadow vole produced uncurated assemblies with scaffold N50 values exceeding 100 million base pairs and telomeric sequence at many scaffold ends.
PacBio (NASDAQ: PACB) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT (1:30 PM ET) in San Francisco.
A live webcast will be available on the company investor site and a replay will be posted for at least 30 days after the event.
PacBio (NASDAQ: PACB) said management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 11:30 AM ET in New York.
A live webcast will be available on the company investor site at investor.pacificbiosciences.com, with a replay accessible for at least 30 days after the event.
PacBio (NASDAQ: PACB) announced management will participate in three investor conferences the week of November 18–19, 2025: Wolfe Research Healthcare Conference in New York, Jefferies Global Healthcare Conference in London, and Stephens Annual Investment Conference in Nashville.
Scheduled events include fireside chats on Nov 18 at 8:40 AM ET (Wolfe) and Nov 19 at 10:00 AM CT (Stephens); Jefferies meetings will be 1x1 sessions on Nov 19. Live webcasts of the fireside chats will be available at the company investor site, with replays available for at least 30 days.